Swiss Biotech Day 2026 arrived at a moment when the global biotech industry is no longer operating under the assumptions that defined the post-pandemic boom years. Public financing remains difficult, IPO activity has slowed dramatically, and investors increasingly expect companies to demonstrate commercial durability—not simply scientific promise. Yet in Basel this year, the tone was not defensive. Instead, discussions across the event reflected a sector attempting to redefine what sustainable biotech growth now looks like: one built less around short-term market momentum and more around translational infrastructure, manufacturing capability, cross-border collaboration, and operational execution.
That shift was visible throughout the conference agenda and reinforced by a newly released Swiss biotech industry report showing that privately funded companies in Switzerland raised a record CHF 1.15 billion in 2025—a 38% increase from the previous year—even as public biotech financing remained constrained. Industry figures also showed Swiss biotech revenues reaching a record CHF 7.5 billion in 2025, while R&D spending remained elevated at CHF 2.5 billion. For many participants, those numbers reinforced a broader message now emerging across the global biotech landscape: capital has not disappeared, but it has become significantly more selective.
Know more.
